Pharma MNCs gear up for product patents, recast their portfolios.
Economic Times (New Delhi, India), April, 2005
Byline: Writankar Mukherjee
Apr. 13--KOLKATA, India -- The multinational pharma majors operating in India have set the ball rolling to improve their bottomlines in the product patent era.
Many companies have initiated restructuring exercises to strengthen their presence in key therapeutic segments in which a spate of patented product launches are planned in coming months.
Aventis, Pfizer, Novartis, Eli Lilly and Organon are re-shaping their product portfolio and marketing divisions as per the strategies of the parent company. In short, the MNCs are trying to replicate here the business model they follow in regulated markets like the US and Europe.
"The product patent regime will require a change in business strategy to improve market...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- Design a commission plan that drives sales - Sales Commissions
